ArriVent Phase 3 Lung Cancer Trial Failed
The firmonertinib study did not meet its primary efficacy endpoint in previously untreated lung cancer patients.
Updated on Oct. 14, 2026 in Cancer
Live Poll
Should medical drug trials be deemed successful if they miss primary goals but show secondary improvements?
ArriVent BioPharma reported that its Phase 3 FURVENT clinical trial failed to meet its primary efficacy endpoint of progression-free survival. The study evaluated firmonertinib in 398 previously untreated patients with non-squamous non-small cell lung cancer.
Why it matters
The trial results create uncertainty regarding the potential use of firmonertinib as a first-line treatment for lung cancer patients. ArriVent BioPharma is currently reviewing the complete trial dataset to determine the next steps for the drug program.
The FURVENT trial enrolled 398 patients to evaluate daily oral doses of 160mg and 240mg of firmonertinib. Severe treatment-emergent adverse events were reported in 52% of the 240mg group, 53% of the 160mg group, and 55% of the chemotherapy arm.
The players
ArriVent BioPharma
Headquartered in Newtown Square, PA, this clinical-stage biopharmaceutical company focuses on developing new medicine for patients with cancer.
The details
The primary endpoint was assessed by blinded independent central review, comparing the drug against standard platinum-based chemotherapy combined with pemetrexed. Study sites included the United States, Europe, and Asia.
Timeline
ArriVent reported the Phase 3 trial failure on October 14, 2026.
Health Landscape
The outcome of the FURVENT clinical trial represents a major hurdle in the evolution of targeted lung cancer therapies. This failure stands in contrast to the success of firmonertinib in other specific markets, highlighting the complexities of advancing first-line cancer treatments.
This trial result means firmonertinib will not advance to regulatory approval for first-line lung cancer treatment at this time. Patients and clinicians should consult with their healthcare providers regarding available standard-of-care options for non-small cell lung cancer.
The takeaway
Clinical trial failures are a common but critical aspect of pharmaceutical research as companies strive to find effective new therapies. Patients should remain focused on existing, approved treatment protocols while researchers analyze data from this specific study.
Further reading
For additional context on oncology developments, visit the Cancer section.
Source note: This article includes information reported by MyChesCo.
Live Poll
Should medical drug trials be deemed successful if they miss primary goals but show secondary improvements?
